In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants
In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants
复制标题
DOI：
10.1128/aac.01440-06
复制
发表时间：
2007-06-01
影响因子：
4.9
通讯作者：
Zoulim, F.
中科院分区：
文献类型：
--
作者：
Brunelle, M. N.;Lucifora, J.;Zoulim, F.
体外评估了耐药乙型肝炎病毒 (HBV) 突变体对拉米夫定、阿德福韦、替诺福韦、恩替卡韦和 2,4-二氨基-6-[2-(膦酰甲氧基)乙氧基]-嘧啶 (PMEO-DAPym)（一种新型无环嘧啶类似物）的敏感性。大多数耐药突变体，包括多重耐药菌株，仍然对替诺福韦和 PMEO-DAPym 敏感。因此，后一种分子对于乙型肝炎病毒感染的治疗值得进一步评估。
The susceptibilities of drug-resistant hepatitis B virus (HBV) mutants to lamivudine, adefovir, tenofovir, entecavir, and 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine (PMEO-DAPym), a novel acyclic pyrimidine analogue, were assessed in vitro. Most drug-resistant mutants, including multidrug-resistant strains, remained sensitive to tenofovir and PMEO-DAPym. Therefore, the latter molecule deserves further evaluation for the treatment of HBV infection.